Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2012 May 30;30 Suppl 2:B67-72. doi: 10.1016/j.vaccine.2011.12.126. Epub 2012 Jan 9.

The challenge of post-implementation surveillance for novel meningococcal vaccines.

Author information

1
Oxford Universities Hospitals NHS Trust, United Kingdom. matthew.snape@paediatrics.ox.ac.uk

Abstract

Novel serogroup B meningococcal vaccines are currently in late stage development and may be used in mass immunisation campaigns over the coming years. This represents an exciting development in the prevention of childhood meningitis, however monitoring the impact of these vaccines on meningococcal disease epidemiology will provide significant challenges. Although designed to prevent serogroup B meningococcal disease the vaccine antigens are not serogroup specific, creating the potential for multiple definitions of vaccine effectiveness and vaccine failure.

PMID:
22230578
DOI:
10.1016/j.vaccine.2011.12.126
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center